Blood–Aqueous Barrier Dynamics After Iris-Directed Laser Exposure: Distinguishing Transient Anterior-Chamber Response From Persistent Inflammation

Anterior-chamber cells and aqueous flare are routinely used as indicators of ocular inflammation, yet their biological significance after iris-directed laser exposure cannot be determined reliably from a single postoperative observation. This mechanistic evidence framework examines blood–aqueous barrier (BAB) dynamics after iris-directed laser exposure and proposes a longitudinal approach for distinguishing a transient, resolving anterior-chamber response from persistent or progressive inflammatory activity. The framework integrates anterior-chamber cells, clinical and quantitative flare, intraocular pressure, corneal status, angle and outflow findings, symptoms, medication context, and timing relative to laser exposure. Particular emphasis is placed on laser flare photometry as an objective measure of aqueous protein-related light scatter and on the distinction between static clinical state and biological trajectory. Available experimental and clinical laser literature demonstrates that measurable anterior-chamber inflammatory responses may occur after iris-directed procedures and may subsequently resolve, but their magnitude and duration vary according to procedure, exposure characteristics, ocular context, and measurement methodology. Accordingly, no universal post-laser recovery interval should be assumed. The central proposition of the framework is that state and trajectory should be interpreted together. A single observation of cells or flare cannot establish whether a response is transient, persistent, recurrent, or progressive. Serial measurements are therefore required to characterize recovery. The framework is hypothesis-generating and does not establish that Lumineyes™ or any other iris-directed laser protocol produces a uniformly self-limited inflammatory response. It instead defines the measurements and temporal architecture required for prospective validation. The proposed framework is positioned alongside the Lumineyes Anterior-Segment Safety Staging (L-SAFE) and Temporal Response Architecture (TRA) frameworks while remaining conceptually distinct: TRA addresses temporal organization of biological response, L-SAFE addresses integrated anterior-segment safety status before staged re-exposure, and the present BAB framework focuses specifically on inflammatory and barrier-related recovery trajectories.